113444-43-2

Basic information

• Product Name: ethyl 2-bromo-3,5-dimethylimidazole-4-carboxylate
• Synonyms: ethyl 2-bromo-3,5-dimethylimidazole-4-carboxylate;Ethyl 2-bromo-1,4-dimethyl-1H-imidazole-5-carboxylate;ethyl2-bromo-1,4-dimethyl-1H-imidazole-5-carboxylate(WX191955)
• CAS NO: 113444-43-2
• Molecular Formula: C₈H₁₁BrN₂O₂
• Molecular Weight: 247.1
• EINECS: -0
• Mol File: 113444-43-2.mol

Chemical Properties

• Boiling Point: 333.2±34.0 °C(Predicted)
• Appearance: /
• Density: 1.52±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 1.58±0.60(Predicted)
• CAS DataBase Reference: ethyl 2-bromo-3,5-dimethylimidazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-bromo-3,5-dimethylimidazole-4-carboxylate(113444-43-2)
• EPA Substance Registry System: ethyl 2-bromo-3,5-dimethylimidazole-4-carboxylate(113444-43-2)

Safety Data

• Hazardous Substances Data: 113444-43-2(Hazardous Substances Data)

Upstream product

• 51605-32-4 Ethyl 5-Methyl-4-imidazolecarboxylate 
• 51605-32-4 ethyl 4⁽⁵⁾-methylimidazole-5⁽⁴⁾-carboxylate 
• 95470-42-1 ethyl 2-bromo-4-methyl-1H-imidazole-5-carboxylate 
• 74-88-4 methyl iodide 
• 35445-32-0 ethyl 1,4-dimethyl-1H-imidazole-5-carboxylate 

Downstream Products

• 1105690-65-0 ethyl 2-(4-(benzyloxy)-2-oxopyridin-1(2H)-yl)-1,4-dimethyl-1H-imidazole-5-carboxylate 
• 1313196-30-3 ethyl 1,4-dimethyl-2-[2-[3-(trifluoromethyl)benzyl]-1-benzothiophen-7-yl]-1H-imidazole-5-carboxylate 
• 1313196-31-4 1,4-dimethyl-2-[2-[3-(trifluoromethyl)benzyl]-1-benzothiophen-7-yl]-1H-imidazolo-5-carboxylic acid 

Relevant articles and documents

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

ORGANIC COMPOUNDS

The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

4-METHYLIMIDAZOL-5-YLCARBONYLGUANIDINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE ISCHEMIC HEART DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT

Disclosed are novel 4-methylimidazol-5- ylcarbonylguanidine derivatives, pharmaceutically acceptable salts thereof, preparation methods thereof, and pharmaceutical composition for the prevention and treatment of ischemic heart diseases, comprising the same as an active ingredient. Having potent inhibitory activity against NHE-I and excellent protective effects on the heart against ischemia/reperfusion, the novel 4-methylimidazol-5- ylcarbonylguanidine derivatives can be used for the prophylaxis and treatment of ischemic cardiac diseases such as myocardiac infarction, arrhythmia, and angina pectoris and can serve as a cardioprotective agent applicable for coronary reperfusion therapy with coronary artery bypass, percutaneous transluminal coronary angioplasty, and/or thrombolytics for myocardiac infarction.

ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA

This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines of formula (I) and their use in therapy.